ARKG is the ticker for the ARK Genomic Revolution ETF, an actively managed exchange-traded fund (ETF) from ARK Invest, the innovation-focused asset manager led by Cathie Wood. An ETF is a fund that trades on a stock exchange like an individual stock but holds a basket of securities. ARKG is designed to give investors broad exposure to companies that ARK believes are positioned to benefit from breakthroughs in genomics — the study of genes, DNA, and how genetic information can be read, edited, and applied to medicine, agriculture, and other industries.
ARKG seeks long-term growth of capital. Under normal circumstances, it invests at least 80% of its assets in domestic and foreign equity securities of companies relevant to the fund's genomics investment theme. These are companies that ARK identifies as extending or enhancing the quality of life through scientific advances in genomics, including gene therapy, genomic sequencing, analysis, synthesis, instrumentation, molecular medicine, bioinformatics, and agricultural biotechnology.
The fund is actively managed, meaning its portfolio managers select individual stocks based on their own research rather than passively tracking an index. ARKG is classified as non-diversified, which allows it to concentrate a meaningful share of its assets in a smaller number of holdings. The fund is part of the ARK ETF Trust and is managed by ARK Investment Management LLC.
ARKG launched on October 31, 2014, and carries a net expense ratio of 0.75% — a fee that represents the annual cost of owning the fund. Its portfolio generally holds roughly 30 to 40 securities, with the largest positions concentrated in life-sciences and biotechnology names. Recent top holdings have included companies such as TWST (Twist Bioscience), CRSP (CRISPR Therapeutics), TEM (Tempus AI), TXG (10x Genomics), and ILMN (Illumina). Holdings are subject to change as managers buy and sell positions.
The fund's sector exposure is overwhelmingly concentrated in healthcare, which has historically represented roughly 90% or more of portfolio holdings, with a smaller allocation to information technology. By market capitalization, ARKG leans toward mid- and small-cap companies, reflecting its focus on emerging and disruptive science rather than large, established firms.
ARKG attracts attention as a way to gain diversified exposure to the genomics theme in a single trade. Rather than picking individual biotechnology stocks, investors can hold a professionally managed basket spanning gene editing, DNA sequencing, precision medicine, and related technologies. This thematic investment strategy appeals to investors who want long-term exposure to scientific innovation but prefer not to concentrate in any single company.
The fund also benefits from ARK Invest's research-driven approach, which combines top-down analysis of disruptive technologies with bottom-up evaluation of individual companies. ARK has described the fund as a potential complement to traditional portfolios because its holdings tend to have relatively low overlap with broad-market indexes, offering differentiated sector and style exposure. For investors who believe genomics will reshape medicine and other industries over the coming decades, ARKG provides a vehicle to express that view.
ARKG carries several risks that investors should understand before committing capital. First, it is highly concentrated in a single sector — healthcare and biotechnology — and within that sector it emphasizes smaller, early-stage companies that may be unprofitable and reliant on raising additional capital. This makes the fund sensitive to shifts in investor sentiment, interest rates, and funding conditions for biotech.
Because it is actively managed and non-diversified, ARKG's performance can diverge sharply from broad market indexes. The fund has historically exhibited high volatility and a relatively high beta, meaning it tends to move more dramatically than the overall market in both directions. Scientific and clinical outcomes — such as failed drug trials or regulatory setbacks — can affect individual holdings, while the thematic nature of the fund means its fortunes are closely tied to the overall health of the genomics industry. The 0.75% expense ratio is also higher than that of many passively managed index ETFs, though it is comparable to other actively managed thematic funds.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that align with their own investment strategies. Whether you are researching thematic funds like ARKG or individual equities, the AI Screener offers a structured way to narrow the universe and focus your analysis.
The ARK Genomic Revolution ETF (ARKG) offers a distinctive, research-driven way to access the genomics theme through an actively managed, non-diversified portfolio of mostly healthcare and life-sciences companies. Its concentrated portfolio holdings, innovation-focused mandate, and high volatility distinguish it from broad-market funds. For investors willing to accept elevated risk in pursuit of long-term exposure to genomics and related technologies, ARKG remains a prominent and closely followed thematic ETF.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Category Health